Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Young A, Lacerda A, Paik J, Popova V, Fu D. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. The International Journal Of Neuropsychopharmacology 2025, 28: pyaf027. PMID: 40319349, PMCID: PMC12143125, DOI: 10.1093/ijnp/pyaf027.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionSustained 3Oral antidepressantNon-treatment-resistant major depressive disorderMontgomery-Asberg Depression Rating ScaleTreatment-resistant depression treatmentEsketamine nasal sprayDepression Rating ScaleMajor depressive disorderLong-term extension studySafety of esketamineLong-term safetyRate of relapseMontgomery-AsbergDepressive disorderDepression severityEsketamine dosesExtension studySuicide riskDepressive symptomsEsketamineRating ScaleMaintenance treatmentAdverse eventsLong-term treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply